Equibles does not estimate personal net worth.
Get an email with a short summary when Arrowhead Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARWR alertsDan Appel is recorded as CFO at Arrowhead Pharmaceuticals, Inc. (ARWR). Dan Appel has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Arrowhead Pharmaceuticals, Inc. on November 12, 2026. Arrowhead Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arrowhead Pharmaceuticals, Inc. includes Christopher Anzalone (CEO and Board Member), Daniel Apel (CFO), Patrick O'Brien (COO) and 7 others.
“I'll provide a brief outline of our financial results for the full fiscal year ended September 30. 2026, and then discuss our financial position following several recent developments.”
“As we reported today, net loss for the quarter into June 30, 2026 was $194.3 million, or loss of $1.36 per share based on 143.4 million fully diluted weighted average shares outstanding.”
“So it's true, we are, you know, if you look at the first full commercial quarter of sales, we are trending better. That's when you normalize for price and look at sort of a unit basis.”
“Thank you, James, and good afternoon, everyone. and provide a brief outline of our financial picture. As we reported today, net income for the quarter ended December 31st, 2025 was $30.8 million or an income of $0.22 per share based on $140.7 million fully diluted weighted average shares outstanding.”
“I'll provide a brief outline of our financial results. As we reported today, our net loss for fiscal year 2025 was $2 million for a loss of $0.01 per share, based on 133.8 million fully diluted weighted average shares outstanding.”
Biotechnology · Healthcare
CFO
